Dr. Brett Howell served as the Former Business Unit President of QSP Solutions at Simulations Plus, Inc., a leading provider of modeling and simulation software and consulting services for pharmaceutical research and development. With a robust background in pharmacology and a Ph.D. from the University of North Carolina at Chapel Hill, Dr. Howell brought a wealth of expertise to his role at Simulations Plus. Before joining the company, he held significant positions in the pharmaceutical industry, including roles at Pfizer and Eli Lilly, where he focused on the development and application of quantitative systems pharmacology (QSP) models to enhance drug discovery and development processes. At Simulations Plus, Dr. Howell was instrumental in leading the QSP Solutions business unit, which specializes in providing advanced modeling and simulation services to help pharmaceutical companies optimize their drug development strategies. Under his leadership, the unit expanded its service offerings and client base, significantly contributing to the company's growth and reputation in the industry. His strategic vision and deep understanding of QSP enabled the team to deliver innovative solutions that addressed complex challenges in drug development, ultimately helping clients make more informed decisions and improve the success rates of their clinical trials. Dr. Howell's contributions to the field of QSP and his leadership at Simulations Plus have been widely recognized. He has authored numerous publications and presented at various international conferences, sharing insights and advancements in QSP modeling. His tenure at Simulations Plus not only advanced the company's capabilities but also solidified its position as a leader in the application of modeling and simulation technologies in pharmaceutical research and development.